Jim Cramer's Top Takeaways: Domino's, GW Pharmaceuticals, Bed Bath & Beyond

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.


NEW YORK (TheStreet) -- Did you miss last night's "Mad Money" on CNBC? If so, here are Jim Cramer's top takeaways for today's trading.

DPZ Chart
DPZ data by YCharts

Domino's Pizza (DPZ), Papa John's (PZZA) and Papa Murphy's (FRSH): Competition is heating up in the pizza wars, with all these pizza giants vying for your business. But with shares of Domino's up 54% for the year, Papa John's up 79% and Papa Murphy's up 128%, which one is the best investment?

The key metric in the pizza business is same-store sales, and among the three Domino's is the clear winner, with not only the strongest but also accelerating sales at its 11,700 locations.

As for the stocks, it just so happens that Domino's is also the cheapest of the three, Cramer said, trading at 28 times earnings, while Papa John's trades at 31 times and Papa Murphy's at 33 times earnings.

Cramer said he can't make a case for owning either of the others and is sticking with Domino's and its CEO Patrick Doyle. That stock is up nearly 1,000% since he first got behind the company's turnaround efforts five and a half years ago.

GWPH Chart
GWPH data by YCharts

GW Pharmaceuticals (GWPH): In an exclusive interview, Cramer sat down with Justin Gover, CEO of GW Pharmaceuticals, the biotech that's studying the medicinal uses of marijuana, with a stock that's up 91% so far in 2015.

Gover explained that GW is pursuing real science, using the marijuana plant as a source for real medications that can treat everything from epilepsy to diabetes and even cancer. None of GW's end products contain THC, the chemical in marijuana that makes you high, Gover continued.

GW's first product, Sativex, is currently in four Phase III trials to treat a drug-resistant form of epilepsy. Gover said those trials will offer important insights into how well Sativex is working when they complete in early 2016.

GW is also making an investment in America, as the British-based firm is building the infrastructure needed to do more clinical work here in the United States. Even Gover himself will be relocating to the U.S. shortly, he noted.

BBBY Chart
BBBY data by YCharts

Bed Bath & Beyond (BBBY): What can investors glean from Bed Bath's most recent quarter? It's that there are simply too many retailers and too much competition in the retail space.

Cramer said he's always been a fan of Bed Bath and has shopped there for years. But if there was a newly remodeled Target (TGT) close by, he'd probably shop there, or just order what he needs from Amazon.com (AMZN) or another retailer.

Customer loyalty is waning, he said, and it's only going to get tougher for retailers. Some stores, like Home Depot (HD), can overcome the trend. Others, like Bed Bath, are only going to see their customers continue to shop wherever is most convenient, which may or may not be at Bed Bath & Beyond.

To read a full recap of "Mad Money" on CNBC, click here.

To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.

To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.

At the time of publication, Cramer's Action Alerts PLUS had a position in TGT.

More from Opinion

Tuesday Turnaround: Micron, Autonomous Driving, and J.C. Penney

Tuesday Turnaround: Micron, Autonomous Driving, and J.C. Penney

Cable Stock Investors Should Keep an Eye On Wireless Broadband's Rise

Cable Stock Investors Should Keep an Eye On Wireless Broadband's Rise

Trump Blinks on China Trade War That's Looking Harder to Win

Trump Blinks on China Trade War That's Looking Harder to Win

Monday Madness: GE, China, and Micron

Monday Madness: GE, China, and Micron

Attention 60 Minutes: Google Isn't the Only Big-Tech Monopoly

Attention 60 Minutes: Google Isn't the Only Big-Tech Monopoly